Immune Design Corp. Forecasted to Earn FY2018 Earnings of ($1.99) Per Share (IMDZ)

Immune Design Corp. (NASDAQ:IMDZ) – Research analysts at Leerink Swann increased their FY2018 EPS estimates for Immune Design Corp. in a note issued to investors on Tuesday. Leerink Swann analyst J. Chang now anticipates that the biotechnology company will earn ($1.99) per share for the year, up from their prior forecast of ($2.22).

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.11. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. WARNING: This story was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/10/21/immune-design-corp-forecasted-to-earn-fy2018-earnings-of-1-99-per-share-imdz.html.

A number of other brokerages have also recently issued reports on IMDZ. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, July 18th. ValuEngine cut shares of Immune Design Corp. from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $29.00 to $10.00 in a report on Tuesday. Jefferies Group LLC reissued a “buy” rating and set a $18.00 target price on shares of Immune Design Corp. in a report on Wednesday, June 28th. Finally, BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Immune Design Corp. has an average rating of “Buy” and an average target price of $14.75.

Shares of Immune Design Corp. (NASDAQ:IMDZ) traded down 5.45% during midday trading on Friday, reaching $5.20. The company had a trading volume of 1,063,103 shares. The firm’s market capitalization is $133.22 million. Immune Design Corp. has a one year low of $4.50 and a one year high of $13.05. The company has a 50 day moving average price of $9.97 and a 200-day moving average price of $8.57.

Several institutional investors have recently added to or reduced their stakes in IMDZ. Wells Fargo & Company MN increased its holdings in shares of Immune Design Corp. by 46.5% in the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock worth $1,012,000 after purchasing an additional 47,266 shares during the period. FMR LLC increased its holdings in shares of Immune Design Corp. by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after purchasing an additional 1,699 shares during the period. TIAA CREF Investment Management LLC increased its holdings in shares of Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 7,236 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after purchasing an additional 70,351 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares during the period. 51.46% of the stock is currently owned by hedge funds and other institutional investors.

In other Immune Design Corp. news, insider Wayne Gombotz sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $11.43, for a total transaction of $114,300.00. Following the sale, the insider now owns 33,054 shares of the company’s stock, valued at approximately $377,807.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.70% of the company’s stock.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply